Drugs / HepA-I
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06442449 | Aug 2024 → Sep 2025 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | Met primary |
| Phase 4 | NCT06460545 | Jun 2024 → Aug 2026 overdue | hepatitis A virus infection, poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HepA-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06442449 ↗ |
| Known as | Inactivated Hepatitis A (Hep-A) Vaccine | “Inactivated Hepatitis A (Hep-A) Vaccine” NCT06442449 ↗ |
| Modality | Vaccine | “Inactivated Hepatitis A (Hep-A) Vaccine” NCT06442449 ↗ |